RAPT Therapeutics, Inc. (RAPT) Financial Analysis & Valuation | Quarter Chart
RAPT Therapeutics, Inc. (RAPT)
RAPTPrice: $58.01
Fair Value: 🔒
🔒score
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif... more
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on dis... more
Description
Shares
| Market Cap | $959.26M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brian Russell Wong |
| IPO Date | 2019-10-31 | CAGR | — |
| Employees | 67 | Website | www.rapt.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
RAPT chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.14B | P/E Ratio | -4.97 |
| Forward P/E | -21.38 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1435411067328548 |
| P/CF Ratio | -2522194691523988 | P/FCF Ratio | -1549240806335259.75 |
| EPS | $-11.66 | EPS Growth 1Y | -50.24% |
| EPS Growth 3Y | -45.66% | EPS Growth 5Y | -38.75% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.62% | ROA | -0.64% |
| ROCE | -0.74% | Current Ratio | 12.04 |
| Quick Ratio | 12.04 | Cash Ratio | 2.84 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 35.08 | Piotroski Score | 3 |